[go: up one dir, main page]

SG11201603479TA - Cell - Google Patents

Cell

Info

Publication number
SG11201603479TA
SG11201603479TA SG11201603479TA SG11201603479TA SG11201603479TA SG 11201603479T A SG11201603479T A SG 11201603479TA SG 11201603479T A SG11201603479T A SG 11201603479TA SG 11201603479T A SG11201603479T A SG 11201603479TA SG 11201603479T A SG11201603479T A SG 11201603479TA
Authority
SG
Singapore
Prior art keywords
cell
Prior art date
Application number
SG11201603479TA
Inventor
Martin Pulé
Khai Kong
Shaun Cordoba
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320573A external-priority patent/GB201320573D0/en
Priority claimed from GB201410934A external-priority patent/GB201410934D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of SG11201603479TA publication Critical patent/SG11201603479TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201603479TA 2013-11-21 2014-11-21 Cell SG11201603479TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201320573A GB201320573D0 (en) 2013-11-21 2013-11-21 T Cell
GB201410934A GB201410934D0 (en) 2014-06-19 2014-06-19 T cell
PCT/GB2014/053452 WO2015075469A1 (en) 2013-11-21 2014-11-21 Cell

Publications (1)

Publication Number Publication Date
SG11201603479TA true SG11201603479TA (en) 2016-05-30

Family

ID=52003983

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603484PA SG11201603484PA (en) 2013-11-21 2014-11-21 Cell
SG11201603479TA SG11201603479TA (en) 2013-11-21 2014-11-21 Cell

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201603484PA SG11201603484PA (en) 2013-11-21 2014-11-21 Cell

Country Status (19)

Country Link
US (10) US10172886B2 (en)
EP (6) EP3071222B1 (en)
JP (4) JP6433498B2 (en)
KR (2) KR101991555B1 (en)
CN (2) CN105848673B (en)
AU (2) AU2014351558B2 (en)
BR (2) BR112016011459A2 (en)
CA (2) CA2929984C (en)
CL (2) CL2016001134A1 (en)
DK (2) DK3071222T3 (en)
ES (2) ES2832586T3 (en)
HU (1) HUE051523T2 (en)
IL (2) IL245572B (en)
MX (2) MX377283B (en)
PL (2) PL3071223T3 (en)
PT (2) PT3071222T (en)
RU (2) RU2732236C2 (en)
SG (2) SG11201603484PA (en)
WO (3) WO2015075468A1 (en)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2683352T3 (en) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale HPV particles and uses thereof
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
EP3517130B1 (en) 2013-09-18 2022-03-30 Aura Biosciences, Inc. Method of producing photosensitive molecules
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
DK3071222T3 (en) 2013-11-21 2020-11-16 Ucl Business Ltd CELL
US10676528B2 (en) * 2013-12-06 2020-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
MX386422B (en) 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center LABELED CHEMICAL EFFECTOR MOLECULES AND THEIR RECEPTORS.
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
MX2017000646A (en) 2014-07-15 2017-04-27 Juno Therapeutics Inc GENETICALLY MODIFIED CELLS FOR ADOPTIVE CELL THERAPY.
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
WO2016097231A2 (en) * 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
CN114107212A (en) * 2014-12-24 2022-03-01 奥托路斯有限公司 Cells
AU2016212158B2 (en) 2015-01-26 2021-06-03 Allogene Therapeutics, Inc. mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
EP3250611B1 (en) * 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
JP6895380B2 (en) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール Methods for Improving the Efficacy of Therapeutic Immune Cells
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
HRP20220893T1 (en) * 2015-04-08 2022-10-14 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US10786549B2 (en) 2015-04-23 2020-09-29 Baylor College Of Medicine CD5 chimeric antigen receptor for adoptive T cell therapy
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
US11827904B2 (en) * 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
AU2016265845B2 (en) * 2015-05-15 2020-10-08 City Of Hope Chimeric antigen receptor compositions
AU2016271147B2 (en) * 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
US11458167B2 (en) * 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR TYPE T LYMPHOCYTES AS SELF-EMERGING AND ALLO-IMMUNITY INTERVENTIONS
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
JP2018532801A (en) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Targeted cancer therapy
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
AU2017225733A1 (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
EP3458077A4 (en) * 2016-05-17 2020-04-01 Chimera Bioengineering Inc. METHOD FOR PRODUCING NEW ANTI-BINDING DOMAINS
JP7114490B2 (en) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー Construction of chimeric antibody receptors (CARs) and methods of their use
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
CN107893052B (en) * 2016-09-09 2023-11-03 科济生物医药（上海）有限公司 Fusion proteins and their applications
US11219646B2 (en) * 2016-09-30 2022-01-11 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US20190352409A1 (en) 2016-11-11 2019-11-21 Autolus Limited Chimeric antigen receptor
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JP7382829B2 (en) 2017-01-10 2023-11-17 ザ ジェネラル ホスピタル コーポレイション T cells expressing chimeric antigen receptors
JP2020506700A (en) * 2017-01-31 2020-03-05 ノバルティス アーゲー Cancer treatment using multispecific chimeric T cell receptor protein
BR112019019917A2 (en) 2017-03-27 2020-04-22 Nat Univ Singapore truncated nkg2d chimeric receptors and their uses in natural killer cell immunotherapy
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP7356354B2 (en) * 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト Materials and methods for the manipulation of cells and their use in immuno-oncology
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
JP7132249B2 (en) * 2017-05-15 2022-09-06 オートラス リミテッド Cells containing chimeric antigen receptors (CAR)
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
JP2020524512A (en) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー Compositions of chimeric antibody receptors (CARs) and methods of use thereof
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
JP2020530291A (en) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール T cell receptor deficiency chimeric antigen receptor T cells and how to use them
CA3077174A1 (en) 2017-09-28 2019-04-04 Immpact-Bio Ltd. A universal platform for preparing an inhibitory chimeric antigen receptor (icar)
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN111132701A (en) 2017-10-25 2020-05-08 锕医药股份有限公司 Anti-CD45-Based Conditioning Approaches and Their Combination with Gene Edited Cell-Based Therapies
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201803079D0 (en) * 2018-02-26 2018-04-11 Autolus Ltd Cell
WO2019177986A1 (en) 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
CN112119096B (en) 2018-05-15 2024-04-30 奥托路斯有限公司 Chimeric Antigen Receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
KR20210008408A (en) 2018-05-23 2021-01-21 싱가포르국립대학교 Blocking of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
CN110615842B (en) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 Chimeric antigen receptor containing co-stimulatory receptor and application thereof
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
JP7560882B2 (en) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール Methods for specifically stimulating survival and expansion of genetically modified immune cells - Patents.com
HUE069503T2 (en) 2018-09-27 2025-03-28 Autolus Ltd Chimeric antigen receptor
CA3109747A1 (en) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3860642A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
KR20210113169A (en) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Treatment method using chimeric antigen receptor specific for Β cell maturation antigen
CN113412117B (en) 2018-12-12 2025-03-04 凯德药业股份有限公司 Chimeric antigens and T cell receptors and methods of use
US20220133791A1 (en) 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
CN118546959A (en) 2019-03-05 2024-08-27 恩卡尔塔公司 CD 19-directed chimeric antigen receptor and use thereof in immunotherapy
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
SG11202111532SA (en) 2019-05-01 2021-11-29 Pact Pharma Inc Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy
CA3140064A1 (en) * 2019-05-16 2020-11-19 University Of Washington Lockr-mediated recruitment of car t cells
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
CN114585371A (en) * 2019-08-20 2022-06-03 森迪生物科学公司 Chimeric inhibitory receptors
WO2021044213A2 (en) * 2019-09-05 2021-03-11 Migal-galilee Research Institute Ltd. Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CN114929752A (en) * 2019-10-08 2022-08-19 省卫生服务机构 Chimeric cytokine receptors
AR120563A1 (en) 2019-11-26 2022-02-23 Novartis Ag CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
US20220411535A1 (en) * 2019-11-26 2022-12-29 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
IL293716A (en) 2019-12-11 2022-08-01 A2 Biotherapeutics Inc lilrb1-based chimeric antigen receptor
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
WO2021168298A1 (en) * 2020-02-20 2021-08-26 Senti Biosciences, Inc. Inhibitory chimeric receptor architectures
CN115397845A (en) * 2020-02-20 2022-11-25 森迪生物科学公司 Inhibitory chimeric receptor architectures
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
US20230310606A1 (en) 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
JP7621461B2 (en) 2020-08-20 2025-01-24 エー２ バイオセラピューティクス， インコーポレイテッド Compositions and methods for treating EGFR positive cancer
MX2023002017A (en) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS.
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating mesothelin positive cancers
US11976297B2 (en) * 2020-09-21 2024-05-07 A2 Biotherapeutics, Inc. Engineered immune cells with receptor cross-talk
WO2022081975A1 (en) * 2020-10-15 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibition of natural killer cell receptors
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022221606A1 (en) 2021-02-16 2023-08-24 A2 Biotherapeutics, Inc. Compositions and methods for treating her2 positive cancers
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
WO2022251377A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
US20240336903A1 (en) * 2021-08-19 2024-10-10 Shandong Boan Biotechnology Co., Ltd. Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
GB202112923D0 (en) 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
ATE338124T1 (en) * 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
CA2468292A1 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
ES2656414T3 (en) * 2010-09-08 2018-02-27 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
IL311390A (en) 2013-03-15 2024-05-01 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
DK3071222T3 (en) 2013-11-21 2020-11-16 Ucl Business Ltd CELL
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell

Also Published As

Publication number Publication date
CA2929984A1 (en) 2015-05-28
PT3071222T (en) 2020-11-20
CN105792840A (en) 2016-07-20
CN105848673A (en) 2016-08-10
US20160296562A1 (en) 2016-10-13
HUE051523T2 (en) 2021-03-01
RU2016124278A (en) 2017-12-22
EP3071222A1 (en) 2016-09-28
PT3071223T (en) 2021-03-25
MX377283B (en) 2025-03-07
RU2717984C2 (en) 2020-03-27
IL245573A0 (en) 2016-06-30
ES2832586T3 (en) 2021-06-10
IL245572B (en) 2019-02-28
CN105792840B (en) 2020-10-13
US20240033289A1 (en) 2024-02-01
AU2014351558A1 (en) 2016-05-26
ES2861501T3 (en) 2021-10-06
EP3071222B1 (en) 2020-10-21
EP3858378A1 (en) 2021-08-04
PL3071223T3 (en) 2021-08-16
KR20160085347A (en) 2016-07-15
US20190038672A1 (en) 2019-02-07
CL2016001134A1 (en) 2017-05-19
DK3071223T3 (en) 2021-03-29
KR101991555B1 (en) 2019-06-20
US20200016204A1 (en) 2020-01-16
PL3071222T3 (en) 2021-04-19
RU2016124280A (en) 2017-12-26
BR112016011460A2 (en) 2017-09-26
EP3858379A1 (en) 2021-08-04
BR112016011459A2 (en) 2017-09-26
SG11201603484PA (en) 2016-05-30
MX2016006303A (en) 2016-11-07
US20200016203A1 (en) 2020-01-16
WO2015075468A1 (en) 2015-05-28
KR20160085348A (en) 2016-07-15
CL2016001135A1 (en) 2016-12-23
US10172885B2 (en) 2019-01-08
WO2015075469A1 (en) 2015-05-28
CA2930215A1 (en) 2015-05-28
IL245572A0 (en) 2016-06-30
US20210187026A1 (en) 2021-06-24
CA2929984C (en) 2021-05-18
US20240033292A1 (en) 2024-02-01
WO2015075470A1 (en) 2015-05-28
HK1223554A1 (en) 2017-08-04
AU2014351558B2 (en) 2018-08-02
HK1223553A1 (en) 2017-08-04
AU2014351557A1 (en) 2016-05-26
JP2019041775A (en) 2019-03-22
MX373687B (en) 2020-07-07
EP3071223B1 (en) 2021-01-13
IL245573B (en) 2018-11-29
MX2016006057A (en) 2016-11-14
US10172886B2 (en) 2019-01-08
EP3626261A1 (en) 2020-03-25
EP3071221A1 (en) 2016-09-28
JP2016538854A (en) 2016-12-15
US20210154229A1 (en) 2021-05-27
AU2014351557B2 (en) 2019-04-18
US20160289294A1 (en) 2016-10-06
JP2021045172A (en) 2021-03-25
JP6433498B2 (en) 2018-12-05
US20160289293A1 (en) 2016-10-06
DK3071222T3 (en) 2020-11-16
CN105848673B (en) 2020-02-14
EP3071223A1 (en) 2016-09-28
RU2732236C2 (en) 2020-09-14
JP6538684B2 (en) 2019-07-03
CA2930215C (en) 2021-04-27
JP2016538855A (en) 2016-12-15
NZ719859A (en) 2020-11-27
KR101962524B1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
IL245572B (en) Cell
AU356417S (en) Battery
AU355447S (en) Case
AU354443S (en) Case
AU354395S (en) Case
EP2946517A4 (en) Avoiding serving cell interruption
SG11201509558VA (en) Back-contact-type solar cell
GB201303814D0 (en) Battery structure
EP2997819A4 (en) Solar bio-greenhouse
PL3044389T3 (en) Mullion-transom structure
SG11201506993TA (en) Tube-fastening structure
IL242777A (en) Construction-set elements
GB2517228B (en) Laminate cell
EP3018750A4 (en) Cell
GB201310031D0 (en) Cell
GB201312332D0 (en) Cell locations
EP3038195A4 (en) Lithium cell
EP2979746A4 (en) Structure
GB201312803D0 (en) Cell component
GB201318954D0 (en) Cell transport
GB201311130D0 (en) Greensleeves I
GB201304302D0 (en) Electrochemical cells
GB201301952D0 (en) Electrochemical cells
GB201304514D0 (en) Cell delivery
GB201317589D0 (en) Cell